Literature DB >> 20508609

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

R Jäger1, H Gisslinger, F Passamonti, E Rumi, T Berg, B Gisslinger, D Pietra, A Harutyunyan, T Klampfl, D Olcaydu, M Cazzola, R Kralovics.   

Abstract

Transformation to acute leukemia is a major complication of myeloproliferative neoplasms (MPNs), however, the genetic changes leading to transformation remain largely unknown. We screened nine patients with post-MPN leukemia for chromosomal aberrations using microarray karyotyping. Deletions on the short arm of chromosome 7 (del7p) emerged as a recurrent defect. We mapped the common deleted region to the IKZF1 gene, which encodes the transcription factor Ikaros. We further examined the frequency of IKZF1 deletions in a total of 29 post-MPN leukemia and 526 MPN patients without transformation and observed a strong association of IKZF1 deletions with post-MPN leukemia in two independent cohorts. Patients with IKZF1 loss showed complex karyotypes, and del7p was a late event in the genetic evolution of the MPN clone. IKZF1 deletions were observed in both undifferentiated and differentiated myeloid cell types, indicating that IKZF1 loss does not cause differentiation arrest but rather renders progenitors susceptible to transformation, most likely through chromosomal instability. Induced Ikzf1 haploinsufficiency in primary murine progenitors resulted in elevated Stat5 phosphorylation and increased cytokine-dependent growth, suggesting that reduced expression of IKZF1 is sufficient to perturb growth regulation. Thus, IKZF1 loss is an important step in the leukemic transformation of a subpopulation of MPN patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20508609     DOI: 10.1038/leu.2010.99

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  53 in total

1.  Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation.

Authors:  P Hirsch; A C Mamez; R Belhocine; S Lapusan; R Tang; L Suner; D Bories; C Marzac; F Fava; O Legrand; M Mohty; L Douay; F Delhommeau
Journal:  Leukemia       Date:  2016-03-01       Impact factor: 11.528

2.  Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.

Authors:  Mandy Brecqueville; Jérôme Rey; Raynier Devillier; Arnaud Guille; Rémi Gillet; José Adélaide; Véronique Gelsi-Boyer; Christine Arnoulet; Max Chaffanet; Marie-Joelle Mozziconacci; Norbert Vey; Daniel Birnbaum; Anne Murati
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

Review 3.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

4.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

5.  Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.

Authors:  Cristina Pérez; Marien Pascual; José Ignacio Martín-Subero; Beatriz Bellosillo; Victor Segura; Eric Delabesse; Sara Álvarez; María José Larrayoz; José Rifón; Juan Cruz Cigudosa; Carles Besses; María José Calasanz; Nicholas C P Cross; Felipe Prósper; Xabier Agirre
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

6.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

Review 7.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

8.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

Review 9.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

10.  Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.

Authors:  Haijun Wang; Chunhua Song; Yali Ding; Xiaokang Pan; Zheng Ge; Bi-Hua Tan; Chandrika Gowda; Mansi Sachdev; Sunil Muthusami; Hongsheng Ouyang; Liangxue Lai; Olivia L Francis; Christopher L Morris; Hisham Abdel-Azim; Glenn Dorsam; Meixian Xiang; Kimberly J Payne; Sinisa Dovat
Journal:  J Biol Chem       Date:  2015-12-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.